Bintrafusp Alfa vs Pembrolizumab for Treatment-Naïve PD-L1–High Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial
J Thorac Oncol 2023 Aug 17;[EPub Ahead of Print], BC Cho, JS Lee, YL Wu, I Cicin, MC Dols, MJ Ahn, K Cuppens, R Veillon, E Nadal, JM Dias, C Martin, M Reck, EB Garon, E Felip, L Paz-Ares, F Mornex, EE Vokes, AA Adjei, C Robinson, M Sato, Y Vugmeyster, A Machl, F Audhuy, S Chaudhary, F BarlesiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.